Lupin has received approval for its Mycophenolic Acid Delayed-Release Tablets USP, 180 mg and 360 mg from the United States Food and Drug Administration (USFDA) to market a generic equivalent of Myfortic Delayed-Release Tablets, 180 mg and 360 mg, of Novartis Pharmaceuticals Corporation. Mycophenolic Acid Delayed-Release Tablets USP, 180 mg and 360 mg (RLD: Myfortic) had an annual sales of approximately $174 million in the U.S. (IQVIA MAT Sept ember 2019).
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1911.70 |
| Dr. Reddys Labs. | 1369.85 |
| Cipla | 1467.55 |
| Zydus Lifesciences | 1148.05 |
| Lupin | 2491.80 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: